0001615219-16-000198.txt : 20160610 0001615219-16-000198.hdr.sgml : 20160610 20160610152254 ACCESSION NUMBER: 0001615219-16-000198 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160607 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20160610 DATE AS OF CHANGE: 20160610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Flex Pharma, Inc. CENTRAL INDEX KEY: 0001615219 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465087339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36812 FILM NUMBER: 161708503 BUSINESS ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: 24TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-874-1821 MAIL ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: 24TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 8-K 1 a20160607form8-k.htm 8-K Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
June 7, 2016
Date of Report (Date of earliest event reported)
 
Flex Pharma, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-36812
 
46-5087339
(State or other jurisdiction
 
(Commission File Number)
 
(IRS Employer Identification No.)
of incorporation)
 
 
 
 
 
800 Boylston Street, 24th Floor
Boston, MA
 
02199
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (617) 874-1821
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 
o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))








Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 7, 2016, Flex Pharma, Inc. (the "Company") held its Annual Meeting of Stockholders at the offices of Cooley LLP, located at 500 Boylston Street, Boston, MA 02116 at 2:00 p.m. local time (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on two proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2016. The following is a brief description of each matter voted upon, and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.

Each of the three nominees for Class I directors was elected to serve on the Company's Board of Directors (the "Board") until the Annual Meeting of Stockholders in 2019 or until his or her respective successor has been duly elected or qualified. The voting results were as follows:
Director Name
Votes For
Votes Withheld
Broker Non-Votes
Mr. Marc Kozin
11,893,261
1,393,133
847,995
Dr. Roderick MacKinnon
12,442,987
843,407
847,995
Ms. Michelle Stacy
12,492,626
793,768
847,995

The Company's stockholders ratified the selection by the Audit Committee of the Board of Ernst &Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2016. The voting results were as follows:
Votes For
Votes Against
Abstentions
Broker Non-Votes
14,082,475
51,874
40
0








SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Flex Pharma, Inc.
 
 
Dated: June 10, 2016
 
 
By:
/s/ Robert Hadfield
 
 
Robert Hadfield
 
 
General Counsel and Secretary